journal article·2018-11-05Open access

Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy

Md. Habban Akhter, Nv Sateesh Madhav, Javed Ahmad

Abstract

The epidermal growth factor receptor (EGFR) is a cell surface receptor belonging to erythroblastic leukemia viral oncogene homologue (ErbB) family of tyrosine kinase. It plays critical role in the regulation of cell proliferation, survival and differentiation. The EGFR receptor is crucial in a variety of tumor development due to unlikely triggered by receptor overexpression, chromosomal mutation and or ligand-dependent receptor dimerization. The EGFR inhibition established a major therapeutic target in cancer therapy. The signal transduction pathway of EGFR is directly involved in tumor pathogenesis and progression. The combinatorial approach with EGFR inhibitors bring novel therapeutic regime with proved clinical efficacy. This critique briefly addressed EGFR receptor characteristics, worldwide report on various cancers and EGFR based potential targeting modalities in skin, breast, ovary, brain, lungs, pancreas, gastric and colorectal tumors and molecular pathways involved in EGFR targeting.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: HER2/EGFR in Cancer Research · Chronic Lymphocytic Leukemia Research · Lung Cancer Treatments and Mutations

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Pharmacy, DIT University, Dehradun, India;

School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India;

Department of Pharmaceutics, Najran University, Najran, Saudi Arabia

References (55)

Show source-provided references
1. The Official Web Site of the Nobel Prize · 1986
2. 10.1016/S0014-4827(02)00105-210.1016/S0014-4827(02)00105-2 ↗
3. 10.2174/13816121380454730310.2174/138161213804547303 ↗
4. 10.1038/3505207310.1038/35052073 ↗
5. 10.1128/MCB.25.17.7734-7742.200510.1128/MCB.25.17.7734-7742.2005 ↗
6. Saha AK · Artif Cells Nanomed and Biotech · 2017 · 1
7. Akhter MH. · 2017
8. 10.3109/21691401.2016.115348310.3109/21691401.2016.1153483 ↗
9. 10.2174/156720180166616090610425410.2174/1567201801666160906104254 ↗
10. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
11. Akhter MH · Artif Cells Nanomed and Biotech · 2018 · 650
12. 10.1186/1471-2407-11-49610.1186/1471-2407-11-496 ↗
13. 10.2217/nnm.10.9010.2217/nnm.10.90 ↗
14. 10.1038/s41598-017-02997-210.1038/s41598-017-02997-2 ↗
15. Pancreatic Cancer Action Network · 2016
16. Haeri A · Trends in Peptide and Protein Sci · 2016 · 1 · 41
17. 10.1021/acs.biomac.5b0141910.1021/acs.biomac.5b01419 ↗
18. 10.18632/oncotarget.1401210.18632/oncotarget.14012 ↗
19. Goñi-de-Cerio F · J Biomed Nanotechnol · 2018 · 46 · 873
20. Globocon comparison –statistics of breast cancer. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
21. 10.3109/1061186X.2013.77826410.3109/1061186X.2013.778264 ↗
22. 10.1371/journal.pone.002407510.1371/journal.pone.0024075 ↗
23. American Cancer Society. Key Statistics for Ovarian Cancer. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html [Accessed on Jan 5, 2018].
24. 10.1016/j.ejps.2009.07.00610.1016/j.ejps.2009.07.006 ↗
25. 10.1016/j.ijpharm.2005.01.04310.1016/j.ijpharm.2005.01.043 ↗
26. 10.1073/pnas.121196210910.1073/pnas.1211962109 ↗
27. 10.1371/journal.pone.016297810.1371/journal.pone.0162978 ↗
28. 10.1080/10717544.2017.137894010.1080/10717544.2017.1378940 ↗
29. Globocan · 2012
30. 10.2147/IJN.S14352910.2147/IJN.S143529 ↗
31. 10.1080/21645515.2016.124955110.1080/21645515.2016.1249551 ↗
32. 10.1016/j.jconrel.2009.07.00510.1016/j.jconrel.2009.07.005 ↗
33. 10.2217/fon-2015-001210.2217/fon-2015-0012 ↗
34. 10.1016/j.csbj.2016.04.00410.1016/j.csbj.2016.04.004 ↗
35. Sirnaomics Inc · 2015
36. 10.1002/smll.20130141710.1002/smll.201301417 ↗
37. 10.1039/C6RA04753J10.1039/C6RA04753J ↗
38. 10.1016/j.ijpharm.2015.01.01610.1016/j.ijpharm.2015.01.016 ↗
39. 10.1016/j.colsurfb.2016.06.01210.1016/j.colsurfb.2016.06.012 ↗
40. 10.3892/ijo.2014.280610.3892/ijo.2014.2806 ↗
41. 10.1039/b918966a10.1039/b918966a ↗
42. 10.1038/srep2546810.1038/srep25468 ↗
43. 10.1016/j.jconrel.2011.08.01410.1016/j.jconrel.2011.08.014 ↗
44. 10.1021/acs.chemmater.7b0295310.1021/acs.chemmater.7b02953 ↗
45. 10.4172/1948-5956.100025610.4172/1948-5956.1000256 ↗
46. 10.1016/j.ijpharm.2015.02.03410.1016/j.ijpharm.2015.02.034 ↗
47. 10.1080/21691401.2017.129684710.1080/21691401.2017.1296847 ↗
48. 10.1172/JCI5922710.1172/JCI59227 ↗
49. 10.1002/cncr.2666110.1002/cncr.26661 ↗
50. 10.1038/nchembio.45310.1038/nchembio.453 ↗
51. 10.5936/csbj.20120400510.5936/csbj.201204005 ↗
52. 10.1016/j.trecan.2016.12.00510.1016/j.trecan.2016.12.005 ↗
53. 10.3390/cancers702053810.3390/cancers7020538 ↗
54. 10.18632/oncotarget.499010.18632/oncotarget.4990 ↗
55. 10.1016/j.jtho.2015.08.00310.1016/j.jtho.2015.08.003 ↗